Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (14)
Poster categories
  • Thematic Poster Session (15)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • x TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • TPS33 (12)
  • TPS34 (10)
  • TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • x TPS66 (7)
  • TPS67 (10)
  • TPS68 (5)
  • TPS69 (11)
  • TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • x TPS91 (3)
18 results
Thumbnail

D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG

Thumbnail

D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population

Thumbnail

D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms

Thumbnail

D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab

Thumbnail

D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity

Thumbnail

D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide

Thumbnail

D1.377 - Folic Acid Allergy: A Rare Case

Thumbnail

D1.378 - Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization

Thumbnail

D3.126 - Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFiRM Score: A Real-Life Cohort Analysis

Thumbnail

D3.129 - Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma

Thumbnail

D3.132 - The impact of biological therapy on the quality of life of patients with severe asthma

Thumbnail

D3.135 - Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience

Thumbnail

D3.137 - The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma

Thumbnail

D3.138 - Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study

Thumbnail

D3.139 - Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study

Thumbnail

- D3.545 - Natural Killer and Dendritic Cells Leverage Synergistic Interactions to Enhance Treatment of Non-Small Cell Lung Cancer

Thumbnail

- D3.547 - Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity

Thumbnail

- D3.548 - Refractory and persistent pruritus in an atopic patient: A red flag for underlying malignancy?

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM